Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN   US0153511094

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2014 09/16/2014 09/17/2014 09/18/2014 09/19/2014 Date
160.42(c) 163.41(c) 161.53(c) 161.56(c) 160.11 Last
1 145 789 928 828 968 119 674 051 897 228 Volume
-1.41% +1.86% -1.15% +0.02% -0.90% Change
More quotes
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders.It focuses on developing products for the treatment of diseases in the... 
Sector
Pharmaceuticals
Calendar
10/23Earnings Release
Surperformance© rating of Alexion Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart ALEXION PHARMACEUTICALS, I
Duration : Period :
Alexion Pharmaceuticals, I Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 197 M
EBIT 2014 1 081 M
Net income 2014 709 M
Finance 2014 1 770 M
Yield 2014 -
Sales 2015 2 684 M
EBIT 2015 1 327 M
Net income 2015 931 M
Finance 2015 2 912 M
Yield 2015 -
PER 2014 47,83
PER 2015 34,75
EV / Sales 2014 13,7x
EV / Sales 2015 10,8x
Capitalization 31 959 M
More Financials
Latest news on ALEXION PHARMACEUTICALS, I
2d ago ALEXION PHARMACEUTICALS : Asfotase Alfa Granted Orphan Drug Designation in Japan
2d ago ALEXION PHARMACEUTICALS : Change in Directors or Principal Officers, Financial S..
2d ago ALEXION PHARMACEUTICALS : Strengthens and Broadens Its Executive Leadership Team
3d ago Roche's $8 billion InterMune buy not a signal for more big deals
5d ago ALEXION PHARMACEUTICALS : Improved Survival Observed in Pediatric Patients with ..
09/11 ALEXION PHARMACEUTICALS : Asfotase Alfa Gets Orphan Drug Designation in Japan
09/10 ALEXION PHARMACEUTICALS : NICE Suggests Commissioning of Eculizumab for Patients..
09/08 ALEXION PHARMACEUTICALS : Asfotase Alfa Granted Orphan Drug Designation in Japan
09/04 ALEXION PHARMACEUTICALS : Initiates Multinational Registration Trial of Eculizum..
09/03 ALEXION PHARMACEUTICALS : NICE Recommends Commissioning of Eculizumab (Soliris®)..
08/28 ALEXION PHARMACEUTICALS : to Present at Investor Conferences
08/25 ALEXION PHARMACEUTICALS : Other Events (form 8-K)
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
Alexion Pharmaceuticals, I : Income Statement Evolution
More Financials
EPS Revisions
Alexion Pharmaceuticals, I : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF